Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | POLQ | O75417 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286074 | 0.90 | MAOB (0.46) | HDAC1HDAC8CNR1GAAPOLB | |
| SCHEMBL23662783 | 0.90 | IAPP (0.53) | HDAC1HDAC8CNR1GAAPOLB | |
| SCHEMBL27860624 | 0.88 | EPHX2 (0.51) | HDAC1HDAC8CNR1GAAPOLB | |
| SCHEMBL24242035 | 0.87 | ALOX5 (0.45) | HDAC1HDAC8CNR1GAAPOLQ | |
| SCHEMBL1953231 | 0.87 | EPHX2 (0.59) | HDAC1HDAC8CNR1GAAPOLB | |
| SCHEMBL29733422 | 0.87 | EPHX2 (0.59) | HDAC1HDAC8CNR1GAAPOLB | |
| SCHEMBL8745933 | 0.87 | HDAC1 (0.44) | HDAC1HDAC8CNR1GAAPOLB | |
| SCHEMBL3233422 | 0.85 | MAOB (0.50) | HDAC1HDAC8CNR1GAAPOLB | |
| SCHEMBL266248 | 0.85 | ALDH1A1 (0.50) | HDAC1HDAC8CNR1GAAPOLB | |
| SCHEMBL30257708 | 0.85 | ALDH1A1 (0.50) | HDAC1HDAC8CNR1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3113767-B1 | MTOR-INDEPENDENT ACTIVATOR OF TFEB FOR AUTOPHAGY ENHANCEMENT AND USES THEREOF | UNIV HONG KONG BAPTIST UNIV (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-9540299-B2 | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-01-10 | — | — | US | disclosed |
| CN-103936819-B | Hepatitis c virus inhibitors | 百时美施贵宝公司 | 2016-11-16 | — | — | CN | disclosed |
| US-9351946-B2 | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2016-05-31 | — | — | US | disclosed |
| WO-2015131848-A1 | MTOR-INDEPENDENT ACTIVATOR OF TFEB FOR AUTOPHAGY ENHANCEMENT AND USES THEREOF | HONG KONG BAPTIST UNIVERSITY (CN) | 2015-09-11 | — | — | WO | disclosed |
| US-20150250741-A1 | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2015-09-10 | — | — | US | disclosed |
| CN-104703980-A | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD | 2015-06-10 | — | — | CN | disclosed |
| CN-102056907-B | Heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2014-12-31 | — | — | CN | disclosed |
| CN-102325765-B | Substituted bicyclic heterocyclic compounds as gamma-secretase modulators | JANSSEN PHARMACEUTICALS INC | 2014-12-24 | — | — | CN | disclosed |
| CN-103998451-A | Substituted bicyclic azaheterocyclic compounds and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2014-08-20 | — | — | CN | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250741-A1 | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | TFEB, SQSTM1, ATG7 | HDAC1 658/4885HDAC8 375/4885CNR1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.